Kálium-Jodid Ep (Potassium Iodide)

Potassium iodide provides a large amount of stable iodide ions that are quickly taken up by the thyroid. This excess iodide temporarily blocks the organification of both stable and radioactive iodine, preventing the thyroid from incorporating harmful radioisotopes and thereby reducing radiation dose to the gland.

The appropriate dose of Kálium-Jodid Ep is determined by a qualified prescriber based on the individual's age, weight, exposure risk, and clinical situation. Healthcare professionals follow national or institutional guidelines to select the correct amount for each specific scenario.

Safety data for potassium iodide in pregnancy and lactation are limited. It should only be used when the potential benefit outweighs any possible risk, and after consultation with a healthcare provider. The prescriber will evaluate the specific circumstances before recommending treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. The sales team then provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Kálium-Jodid Ep provides potassium iodide in an oral form, similar to other stable iodine tablets used for thyroid protection. Compared with liquid iodine solutions such as Lugol’s, the tablet format offers convenient dosing and storage. Efficacy in blocking radioactive iodine uptake is comparable when administered at the recommended dose and timing.

Store Kálium-Jodid Ep at ambient temperature below 25 °C, in its original packaging, and protect it from moisture and direct sunlight. Keep the product out of reach of children and avoid exposure to extreme heat or humidity, which could affect tablet integrity.

Kálium-Jodid Ep is taken orally, usually with a glass of water. The tablet should be swallowed whole and not chewed or crushed unless otherwise instructed by a healthcare professional. Administration timing is critical; it is most effective when taken shortly before or immediately after potential radioactive iodine exposure.

Serious risks include severe allergic reactions (such as anaphylaxis), significant swelling of the face or throat, breathing difficulties, and disturbances in thyroid function that can lead to hypo‑ or hyper‑thyroidism. In patients with kidney disease, there is a risk of hyperkalemia, which requires close monitoring.

Individuals with a known hypersensitivity to potassium iodide or any component of the formulation should avoid use. Those with severe renal impairment, uncontrolled hyperthyroidism, or certain cardiovascular conditions may be contraindicated. A healthcare professional should evaluate each patient’s medical history before prescribing.